Cas:67808-31-5 methyl 3-cyanothiophene-2-carboxylate manufacturer & supplier

We serve Chemical Name:methyl 3-cyanothiophene-2-carboxylate CAS:67808-31-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

methyl 3-cyanothiophene-2-carboxylate

Chemical Name:methyl 3-cyanothiophene-2-carboxylate
CAS.NO:67808-31-5
Synonyms:QC-6744;methyl 3-cyano-2-thiophenecarboxylate
Molecular Formula:C7H5NO2S
Molecular Weight:167.18500
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:78.33000
Exact Mass:167.00400
LogP:1.40638

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like QC-6744 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,methyl 3-cyano-2-thiophenecarboxylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,methyl 3-cyano-2-thiophenecarboxylate Use and application,QC-6744 technical grade,usp/ep/jp grade.


Related News: Global Empowerment Mission, in phase three of the rehabilitation efforts for those who lost everything is partnering with The Shul of Bal Harbour, and funding partners EZS Events, Ygrene, and Hatzalah of South Florida to provide aid in the form of first and last month payments as well as security deposits on annual leases. 2,2,2-trichloroethyl (6R,7R)-3-azido-8-oxo-7-(2-(thiophen-2-yl)acetamido)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate manufacturers AZ’s chief financial officer and incoming Alexion head Marc Dunoyer acknowledged that the reimbursement infrastructure for rare disease drugs in China isn’t as advanced as it is in many developed economies. The rare disease market in China is still small, but there’s a growing recognition of its importance from authorities, he added. N,N’-Bis-(3,4,5,6-tetrachloro-2-pyridyl)-hydrazin suppliers Soliris, first approved for generalized myasthenia gravis (gMG) in 2017, carries a list price of about $470,000 annually. But to ICER, that cost is “well beyond typical thresholds.” exo-(1R,5S)-3-(4-{(5S)-5-[(acetylamino)methyl]-2-oxo-1,3-oxazolidin-3-yl}-2,6-difluorophenyl)-N-benzyloxy-3-azabicyclo[3.1.0]hexane-6-carboxamide vendor & factory.